PRÉCIS {#s1}
======

Parkinson disease in pregnancy and its management

Teaching Points {#s2}
===============

1.  Parkinson disease is a rare occurrence during pregnancy.

2.  The change in PD symptoms during pregnancy is unpredictable and there is poor knowledge about the correct management of pregnancy in PD.

3.  According to the current literature, L-DOPA therapy should be the best option for patients in terms of safety and efficacy.

Introduction {#s3}
============

Parkinson\'s disease (PD) is the second most common neurodegenerative disorder. It is caused by the degeneration of dopaminergic neurons in the substantia nigra pars compacta of the midbrain ([@B1]). While PD is usually thought as a disease characterized by cardinal motor symptoms including resting tremor, slowness motor (bradykinesia), and rigidity, a wide range of non-motor symptoms such as autonomic, sensory, sleep, and neuropsychiatric dysfunctions are now widely recognized as part of the clinical manifestations ([@B2]). PD frequently affects elderly people (\>60 years), and its prevalence is heavily age-dependent, but \~5% of patients diagnosed with PD are under 40 years of age ([@B3]--[@B5]).

PD in young people is frequently under-diagnosed, but the interest in the disease onset among younger people is constantly growing. In addition, there is a somewhat greater incidence of PD in males than females, with an approximate ratio of 1.5:1 reported in literature ([@B6]--[@B8]). The reason for this gender difference is still unclear, but it supports the hypothesis that estrogen exerts a neuroprotective action through antioxidative, anti-inflammation, and anti-apoptotic pathways ([@B7], [@B9], [@B10]). Estrogen also enhances dopaminergic functions by increasing dopamine synthesis and its release, by inhibiting dopamine re-uptake and by modulating dopamine receptors density and sensitivity, as demonstrated in animal studies ([@B11], [@B12]). Nevertheless, the exact role of estrogens in dopaminergic functions needs to be further clarified ([@B13], [@B14]).

Considering these epidemiological features, pregnancy in PD is a rare occurrence, and to date, clinical experience with its management is rather limited. In clinical practice, doubts concern mainly the impact of PD on gestation, labor, and delivery, as well as the safety of dopaminergic drugs. Moreover, the change in PD symptoms during pregnancy is unpredictable and there is still very poor knowledge among obstetricians about the correct management of pregnancy in PD ([@B15]). Unfortunately, the available evidence from reported cases is mainly formed by retrospective questionnaires or analyses of patients with PD who have been pregnant ([@B16]--[@B19]). In any case, the majority of cases reported in the literature ended in successful full-term deliveries.

Case {#s4}
====

We report the case of a 40-year-old woman with an 8-year history of PD. The disease began with resting tremor and rigidity of her left upper extremity. There was no history of tobacco, drug, or alcohol consumption. She became pregnant for the first time when she was on antiparkinsonian therapy. She referred to us when she was 39 years old. A brain magnetic resonance performed at the beginning of her motor symptoms was normal. Genetic testing to investigate the monogenic form of PD was not performed because of the patient\'s refusal. She responded well to treatment as assessed by the Unifield Parkinson\'s Disease Rating Scale (UPDRS) motor section (part III), the most widely used measure to assess motor symptoms and signs in PD ([@B20]). She had a UPDRS part III score of 39 in the "off" status (phases with important motor symptoms and no response to medication) assessed in the morning before therapy assumption and a score of 22 in the "on" state (stages with good response to medication and few symptoms) after medication intake. When she became pregnant, she was taking 300/75 mg/day of L-DOPA/carbidopa and her motor examination revealed asymmetrical bilateral tremor, rigidity, and bradykinesia predominant on the left side. In the first trimester of her pregnancy, her motor status was similar to the pre-conceptional period. In gestation week 16, her motor status dramatically worsened (stronger rigidity, resting tremor, and onset of gait disturbance such as shuffling with her left leg) and she complained of predictable "off" periods in the afternoon. For this reason, the dose of L-DOPA/carbidopa was increased up to 500/125 mg per day. At 39 gestational weeks, she gave birth to a healthy girl with an Apgar score of 9 by an uncomplicated cesarean delivery chosen instead of a vaginal delivery because of her motor impairment. General and neurological examination of the baby revealed no abnormalities and the routine blood tests were normal. The child was not breast fed to avoid exposure to antiparkinsonian drugs, but medical information on this topic is lacking. The L-DOPA/carbidopa dosage remained constant during the postpartum period and the patient\'s neurological status is currently stable.

Systematic Review {#s5}
=================

We performed a systematic review of the literature using Ovid Medline, Scopus, and PubMed (including Cochrane database). Relevant articles describing any case of PD in pregnancy were identified from the above databases without any time, language, or study limitations. We used the search terms "Parkinson disease" AND "pregnancy." All non-duplicate identified articles were independently reviewed by two authors (S.O. and S.X.), and relevant articles were selected by mutual agreement. Studies were deemed eligible for inclusion in our review if they described at least one case of PD in pregnancy. We analyzed the age of patients, medication, change in PD symptoms during pregnancy, perinatal outcome, and breastfeeding.

We identified 20 studies of PD in pregnancy with a total of 38 pregnant women with PD and 53 pregnancies ([Supplementary Data 1--3](#SM1){ref-type="supplementary-material"}). Therapy in PD is symptomatic and includes L-DOPA usually combined with a peripheral dopa-decarboxilase inhibitor (carbidopa or benserazide), monoamine oxidase-B (MAO-B) inhibitors (selegine and rasagiline), dopamine agonists commonly subdivided into ergot derivatives (bromocriptina, pergolide, cabergolina, and lisuride), and non-ergot derivatives (pramipexole, ropinirole, rotigotine, and apomorphine), amantadine, catechol-O-methyltransferase inhibitors (COMT) (entacapone or polecapone), and anticholinergic drugs. All antiparkinsonian medications are contraindicated during pregnancy and are regarded by the Food and Drug Administration (FDA) as Pregnancy Category C, due to the lack of human or animal evidence regarding their consequences on fetal development ([@B21]).

L-DOPA and Dopa-Decarboxylase Inhibitors ([Table 1](#T1){ref-type="table"})
---------------------------------------------------------------------------

There is no doubt that levodopa is the most efficient medication for PD. Many studies use L-DOPA alone or combined with dopa-decarboxylase inhibitors (carbidopa or benserazide) for PD in pregnancy. Of the 38 women with PD in pregnancy, only 14 use L-DOPA in monotherapy or combined with dopa-decarboxylase inhibitors (36.8%). Although some animal studies ([@B28], [@B29]) have shown that high doses of L-DOPA in monotherapy or combined with peripheral dopa-decarboxylase inhibitors may lead to intrauterine growth retardation or teratogenic effects as malformation of the circulatory system and skeleton malformation ([@B15]), several reports hypothesized that the use of L-DOPA in humans during pregnancy might be safe ([@B16]--[@B18], [@B22]--[@B25]). There is only one case report in the literature on the use of continuous intestinal infusion of L-DOPA/carbidopa gel treatment during pregnancy, after a percutaneous gastrojejunostomy ([@B27]). L-DOPA crosses the placenta and is found in fetal tissues ([@B30]). By contrast, carbidopa and benserazide are found at high concentrations in the umbilical cord, but in very low concentrations in fetal tissue, indicating that the placenta works as a defense barrier ([@B28]--[@B30]). Animal studies have shown that L-DOPA treatment was not associated with a deleterious effect on pregnancy and on fetus. However, two cases of miscarriage in the first trimester ([@B23], [@B26]) and one case of fetal osteomalacia were reported during L-DOPA in monotherapy or with dopa-decarboxylase treatment ([@B15]).

###### 

L-DOPA for PD in pregnancy in monotherapy or combined with decarboxylase inhibitors.

        **References**                 **Medication during pregnancy**          **Change of therapy**
  ----- ------------------------------ ---------------------------------------- -----------------------------------------
  1a    Cook and Klawans ([@B22])      L-DOPA/CARBIDOPA                         Increase L-DOPA dosage during pregnancy
  2b                                   L-DOPA                                   None
  2c                                   L-DOPA                                   None
  3a    Gershanik and Leist ([@B23])   L-DOPA/CARBIDOPA                         None
  3b                                   L-DOPA/CARBIDOPA                         None
  4     Golbe ([@B16])                 L-DOPA/CARBIDOPA                         None
  5                                    L-DOPA/CARBIDOPA                         None
  6                                    L-DOPA/CARBIDOPA                         None
  7                                    L-DOPA/CARBIDOPA                         None
  8a                                   L-DOPA/CARBIDOPA                         None
  8b                                   L-DOPA/CARBIDOPA                         None
  9     Allain et al. ([@B17])         L-DOPA/BENSERAZIDE                       None
  10    Ball and Sagar ([@B18])        L-DOPA/CARBIDOPA                         None
  11    Shulman et al. ([@B24])        L-DOPA/CARBIDOPA                         Increase L-DOPA dosage during pregnancy
  12a   Campos-Sousa et al. ([@B25])   L-DOPA                                   None
  12b                                  L-DOPA                                   None
  12c                                  L-DOPA                                   None
  12d                                  L-DOPA                                   None
  13    Robottom et al. ([@B26])       L-DOPA                                   None
  14    Zlotnik et al. ([@B27])        L-DOPA/CARBIDOPA INTESTINAL GEL (LCIG)   None

Dopamine Agonists ([Table 2](#T2){ref-type="table"})
----------------------------------------------------

Few successful reports, nine studies in literature ([@B15], [@B16], [@B31]--[@B37]), indicate that dopamine agonists (such as bromocriptine, pergolide, pramipexole, cabergolina, and ropinirole) have been used in pregnancy in monotherapy or in association with L-DOPA alone or with dopa-decarboxylase inhibitors without adverse effects on fetal development ([@B31]--[@B34], [@B36], [@B37]). Studies conducted on mice have shown that Pergolide is associated with a 7% reduction of average fetal body weight of the mother, but there is no evidence of any harm to their fetuses ([@B38]). Bromocriptine has been widely used to facilitate pregnancy in women with hyperprolactinemia ([@B39]). No evidence of teratogenic effect or major complications of gestation were reported with the use of bromocriptine in human or animals ([@B31], [@B39]). There is no report of a teratogenic effect of pramipexole therapy during pregnancy in animals and there is no data with the use of rotigotine or apomorphine in pregnancy.

###### 

Use of dopamine agonist for PD in pregnancy.

       **References**                  **Medication during pregnancy**                 **Change of therapy during pregnancy**
  ---- ------------------------------- ----------------------------------------------- -----------------------------------------------------------------------------------------------------------
  1    Golbe ([@B16])                  BROMOCRIPTINE                                   None
  2    Hagell et al. ([@B15])          L-DOPA/BENSERAZIDE + BROMOCRIPTINE              Bromocriptine was discontinued in the 2nd month of pregnancy During pregnancy was increased L-DOPA dosage
  3    Benito-Leon et al. ([@B31])     BROMOCRIPTINE                                   None
  4    De Mari et al. ([@B32])         L-DOPA + PERGOLIDE                              None
  5a   Scott and Chowedhury ([@B33])   L-DOPA/CARBIDOPA + CABERGOLINE                  None
  5b                                   L-DOPA/CARBIDOPA + CABERGOLINE                  None
  6    Mucchiut et al. ([@B34])        PRAMIPEXOLE                                     None
  7    Lindh ([@B35])                  L-DOPA/CARBIDOPA + ENTACAPONE + BROMOCRIPTINA   None
  8    Asha et al. ([@B36])            L-DOPA/CARBIDOPA, BROMOCRIPTINA + ROPINIROLE    None
  9    Bernbir et al. ([@B37])         PRAMIPEXOLE                                     None

MAO-B Inhibitors ([Table 3](#T3){ref-type="table"})
---------------------------------------------------

MAO-B inhibitors (selegine and rasagiline) are used as monotherapy or as added therapy. Animal studies of MAO-B inhibitors have evidenced mild to seriously harmful neurobehavioral effects ([@B19]). No study has been published on treatment with selegine alone in pregnant animals. Only two studies ([@B19], [@B40]) report the use of selegine associated with L-DOPA in woman with PD in pregnancy, with no evidence of harmful effect for the fetus and the mother.

###### 

Use of MAO-B inhibitors for PD in pregnancy.

      **References**               **Medications during pregnancy**                              **Change of therapy during pregnancy**
  --- ---------------------------- ------------------------------------------------------------- ----------------------------------------
  1   Kupsch and Oertel ([@B19])   L-DOPA/BENSERAZIDE + SELEGINE                                 None
  2   Serikawa et al. ([@B40])     L-DOPA/CARBIDOPA until 19th week, then ENATCAPONE+ SELEGINE   Increase dose of L-DOPA/carbidopa

COMT Inhibitors ([Table 4](#T4){ref-type="table"})
--------------------------------------------------

COMT is an enzyme for peripheral metabolism of levodopa. COMT inhibitors are always used in association with levodopa and carbidopa. There is only one report in the literature that uses COMT inhibitor in association with selegine starting at the 19th week of pregnancy in a spontaneous dichorionic/diamniotic twin pregnancy, with the delivery of healthy male twins ([@B40]).

###### 

Use of COMT inhibitors for PD in pregnancy.

      **Reference**              **Medications during pregnancy**           **Change of therapy during pregnancy**
  --- -------------------------- ------------------------------------------ ----------------------------------------------------------------
  1   Serikawa et al. ([@B40])   L-DOPA/CARBIDOPA + ENTACAPONE + SELEGINE   L-DOPA/CARBIDOPA until 19th week, then + ENATCAPONE + SELEGINE

Amantidine ([Table 5](#T5){ref-type="table"})
---------------------------------------------

Amantidine is originally introduced as an antiviral medication. It was accidentally found that the drug is able to relieve PD early symptoms. Amantidine seems to be teratogenic in both animals and humans ([@B42]), because it increases the risk of complications and malformations during pregnancy (especially in the first trimester). Amantidine should be avoided before conception and during gestation and breast feeding. Skeletal developmental defects have been reported in the offspring of rats receiving amantidine in high doses ([@B42]). We found two studies ([@B16], [@B41]) using amantidine in monotherapy or combined with other medications in pregnant women with PD.

###### 

Use of amantidine for PD in pregnancy.

      **References**         **Medications during pregnancy**   **Change of therapy during pregnancy**
  --- ---------------------- ---------------------------------- ----------------------------------------
  1   Nora et al. ([@B41])   AMANTIDINE                         None
  2   Golbe ([@B16])         L-DOPA/CARBIDOPA + AMANTIDINE      None
                             L-DOPA + AMANTIDINE                None
                             AMANTIDINE                         None
                             AMANTIDINE + TRIHEXYPHENIDYL       None

Anticholinergics ([Table 6](#T6){ref-type="table"})
---------------------------------------------------

Clinical use of anticholinergics is limited due to adverse effects. In the few reports on anticholinergic drugs in pregnant women with PD ([@B16]), they are used either as monotherapy or as adjunctive treatment. Trihexyphenidyl, diphenhydramine, procyclidine, benztropine mesylate, hydrochloride, and biperiden hydrochloride or antihistaminic derivatives such as diparalene are commonly used. Most anticholinergics are pregnancy category B2, but their safety in pregnancy has not been well-established ([@B21]). Except for one case of spontaneous miscarriage and a case of probable molar pregnancy, all pregnancies were successful ([@B16]).

###### 

Use of anticholinergics for PD in pregnancy.

      **References**   **Medications during pregnancy**    **Change of therapy during pregnancy**
  --- ---------------- ----------------------------------- ----------------------------------------
  1   Golbe ([@B16])   TRIHEXYPHENIDYL                     None
                       PROCICLIDINE                        None
                       TRIHEXYPHENIDYL + DIPHENHYDRAMINE   None
                       TRIHEXYPHENIDYL + DIPHENHYDRAMINE   None
                       TRIHEXYPHENIDYL + DIPHENHYDRAMINE   None
                       AMANTIDINE + TRIHEXYPHENIDYL        None

In the limited literature available, the effect of pregnancy on PD symptoms seems to be quite controversial ([Table 7](#T7){ref-type="table"}). In 9 of the 53 pregnancies described (17.0%), no antiparkinsonian drug was used ([@B16], [@B22], [@B26], [@B27]). Two studies (two pregnant women) did not evaluate the change of PD symptoms during pregnancy ([@B23], [@B41]). In 28 (52.8%) out of 53 pregnancies, symptoms did not change during pregnancy ([@B16], [@B18], [@B22], [@B25]--[@B27], [@B31]--[@B33], [@B35]--[@B37]); in 3 women (5.7%), some improvement was evidenced ([@B16], [@B19]); and in 21 cases (39.6%), a significant worsening of PD during pregnancy was described ([@B15]--[@B17], [@B23], [@B24], [@B26], [@B27], [@B34], [@B40]). About complications of pregnancy in women suffering from PD and treated with antiparkinsonian agents during gestation, [Table 7](#T7){ref-type="table"} summarizes the results found in the literature. All studies reported pregnancy complications except one study ([@B41]). Most women (68.6%) completed their pregnancy without complications ([@B15]--[@B19], [@B22]--[@B27], [@B31]--[@B37]). Described complications were Trisomy 21 in one case ([@B16]), placenta abruption in one case ([@B33]), preeclampsia and dystocia in one case ([@B16]), and depression with nausea and vomiting in one case ([@B16]). The most common complication was miscarriage (8.0%) ([@B16], [@B23], [@B26]) and spotting in the first trimester (6.0%) ([@B16], [@B22]).

###### 

Change in PD symptoms and complications during pregnancy.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
        **References**                  **Medications during pregnancy**                                           **Change in PD during pregnancy**                              **Complications during pregnancy**
  ----- ------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------------
  1     Nora et al. ([@B41])            AMANTIDINE                                                                 NS                                                             NS

  2a    Cook and Klawans ([@B22])       None                                                                       None                                                           None

  2b                                    L-DOPA/CARBIDOPA                                                           None                                                           Spotting in the 1st trimester

  3a                                    L-DOPA                                                                     None                                                           None

  3b                                    L-DOPA                                                                     None                                                           None

  4a    Gershanik and Leist ([@B23])    L-DOPA/CARBIDOPA                                                           Worsening of "wearing off" effect                              None

  4b                                    L-DOPA/CARBIDOPA                                                           NS                                                             Miscarriage at the 2nd month

  5     Golbe ([@B16])                  L-DOPA/CARBIDOPA                                                           Transient increase in "OFF" time                               Spotting in the 1st trimester

  6                                     L-DOPA/CARBIDOPA                                                           Transient worsening of Corhea                                  None

  7                                     L-DOPA/CARBIDOPA                                                           None                                                           None

  8                                     L-DOPA/CARBIDOPA                                                           Gait worsened                                                  Depression (until delivery), nausea and vomiting at 8--9 months

  9a                                    L-DOPA/CARBIDOPA                                                           Rigidity worsened                                              None

  9b                                    L-DOPA/CARBIDOPA                                                           None                                                           None (elective abortion at the 1st trimester)

  9c                                    L-DOPA/CARBIDOPA + AMANTIDINE                                              "ON" state worsened                                            Preeclampsia

  10a                                   L-DOPA + AMANTIDINE                                                        None                                                           Miscarriage at 4 months

  10b                                   TRIHEXYPHENIDYL                                                            None                                                           None

  10c                                   PROCICLYDINE                                                               None                                                           None

  11                                    None                                                                       Tremor began                                                   Dystocia

  12                                    AMANTIDINE                                                                 Dexterity improved transiently                                 Spotting in the 1st trimester

  13                                    DIPARALENE                                                                 Rigidity worsened slightly                                     None

  14a                                   TRIHEXYPHENIDYL + DIPHENHYDRAMINE                                          Gait slowed                                                    None

  14b                                   TRIHEXYPHENIDYL + DIPHENHYDRAMINE                                          General rigidity worsened                                      None

  15                                    None                                                                       Bradykinesia began, transient resting tremor during labor      None

  16                                    None                                                                       Micrographia, gait, gait difficult began soon after delivery   None

  17                                    None                                                                       Dexterity worsened, nausea all pregnancy, depression           None

  18                                    None                                                                       None                                                           None

  19                                    TRIHEXYPHENIDYL + DIPHENHYDRAMINE                                          None                                                           Spontaneous miscarriage in 4 months

  20                                    AMANTIDINE + TRIHEXYPHENIDYL                                               None                                                           Probable molar pregnancy

  21a                                   None                                                                       None                                                           None (elective abortion at 10 weeks)

  21b                                   BROMOCRIPTINE                                                              None                                                           None (elective abortion at 10 weeks)

  22                                    AMITRIPTYLINE                                                              Mood improved                                                  Trisomy 21 on amniocentesis (elective abortion)

  23    Allain et al. ([@B17])          L-DOPA/BENSERAZIDE                                                         Motor status worsened, depression began                        None

  24    Ball and Sagar ([@B18])         L-DOPA/CARBIDOPA                                                           None                                                           None

  25    Hagell et al. ([@B15])          L-DOPA/BENSERAZIDE+\                                                       Transient depression, increased L-DOPA dosage                  None
                                        BROMOCRIPTINE (bromocriptine discontinued in the 2nd month of pregnancy)                                                                  

  26    Kupsch and Oertel ([@B19])      L-DOPA/BENSERAZIDE + SELEGINE                                              Improving symptoms                                             None

  27    Benito-Leon et al. ([@B31])     BROMOCRIPTINE                                                              None                                                           None

  28    Shulman et al. ([@B24])         L-DOPA/CARBIDOPA                                                           Increased motor dysfunctions, increased L-DOPA dosage          None

  29    De Mari et al. ([@B32])         L-DOPA + PERGOLIDE                                                         None                                                           None

  30    Mucchiut et al. ([@B34])        PRAMIPEXOLE                                                                Motor disability worsened                                      None

  31a   Scott and Chowedhury ([@B33])   L-DOPA/CARBIDOPA + CABERGOLINE                                             None                                                           None

  31b                                   L-DOPA/CARBIDOPA + CABERGOLINE                                             None                                                           Placental abruption at 32 weeks

  32    Lindh ([@B35])                  L-DOPA/CARBIDOPA + ENTACAPONE + BROMOCRIPTINA                              None                                                           None

  33a   Campos-Sousa et al. ([@B25])    L-DOPA                                                                     None                                                           None

  33b                                   L-DOPA                                                                     None                                                           None

  33c                                   L-DOPA                                                                     None                                                           None

  33d                                   L-DOPA                                                                     None                                                           None

  34a   Robottom et al. ([@B26])        L-DOPA                                                                     None                                                           Spontaneous miscarriage at 11 weeks

  34b                                   None                                                                       Motor disability worsened                                      None

  35    Asha et al. ([@B36])            L-DOPA/CARBIDOPA, BROMOCRIPTINE and ROPINIROLE                             None                                                           None (IVF pregnancy)

  36    Serikawa et al. ([@B40])        L-DOPA/CARBIDOPA until 19th weeks then + ENATCAPONE + SELEGINE             Motor disability worsened                                      Preterm premature rupture of the membranes

  37    Bernbir et al. ([@B37])         PRAMIPEXOLE                                                                None                                                           None

  38a   Zlotnik et al. ([@B27])         None                                                                       None                                                           None

  38b                                   Levodopa--carbidopaintestinal gel (LCIG)                                   Severe dyskinesia during labor                                 None
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Analyzing the data in the literature, quite a few case reports showed worsening during intrapartum or postpartum period ([@B16], [@B24], [@B26], [@B27], [@B34], [@B40]). The main complication in the postpartum period was depression ([@B16], [@B24]) ([Table 8](#T8){ref-type="table"}). Most of the reported cases showed no teratogenic effect of drugs on the fetus resulting in an uncomplicated birth of a healthy baby. In one case, the use of amantidine was associated with fetal cardiovascular malformation (a single ventricle with pulmonary atresia) ([@B41]). carbidopa/levodopa administration was associated with one case of osteomalacia ([@B15]). A single case of seizure was reported in a newborn exposed to bromocriptine plus a combination of levodopa, carbidopa, and entacapone ([@B35]) and a woman treated with L-DOPA/carbidopa until 19 weeks of pregnancy and then with enatcapone and selegine gave birth to an infant with ventricular septum defect ([@B40]). Breast feeding is inhibited by dopamine agonists, because they inhibit physiologic lactation ([@B43]). Amantidine is known to enter breast milk in low quantities, but there is no report of adverse effects in breast-fed infants ([@B43], [@B44]). It is not known whether L-DOPA, selegine, or peripheral dopa decarboxylase inhibitors are excreted into breast milk ([@B45], [@B46]).

###### 

Perinatal outcome and breast feeding.

        **References**                  **Mode of delivery**                                                 **Complication intrapartum**            **Postpartum period**                       **Perinatal outcome**                                     **Breast feeding**
  ----- ------------------------------- -------------------------------------------------------------------- --------------------------------------- ------------------------------------------- --------------------------------------------------------- --------------------
  1     Nora et al. ([@B41])            NS                                                                   NS                                      NS                                          Single ventricle with pulmonary atresia                   NS
  2a    Cook and Klawans ([@B22])       Term spontaneous VD                                                  None                                    NS                                                                                                    None
  2b                                    Term spontaneous VD                                                  None                                    NS                                                                                                    None
  3a                                    Term spontaneous VD                                                  None                                    NS                                                                                                    None
  3b                                    Term spontaneous VD                                                  None                                    NS                                                                                                    None
  4     Gershanik and Leist ([@B23])    Term spontaneous VD                                                  None                                    None                                                                                                  NS
  5     Golbe ([@B16])                  Term CD                                                              Inadequate progression in labor         None                                        Healthy                                                   None
  6                                     Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  7                                     Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  8                                     Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  9a                                    Term spontaneous VD                                                  Rigidity worsened                       None                                        Healthy                                                   None
  9b                                    Term spontaneous VD                                                  Preeclampsia                            /                                           Inguinal hernia                                           None
  10a                                   Term spontaneous VD                                                  None                                    Mild postpartum depression                  Healthy                                                   None
  10b                                   Term spontaneous VD                                                  None                                    Mild postpartum depression                  Healthy                                                   None
  11                                    CD for dynamic dystocia                                              Dystocia                                Post-partum depression for 2--3 days        Healthy                                                   None
  12                                    Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  13                                    Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  14                                    Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  15a                                   Term spontaneous VD                                                  None                                    Post-partum depression                      Healthy                                                   None
  15b                                   Term spontaneous VD                                                  Transient resting tremor during labor   None                                        Healthy                                                   None
  16                                    Term spontaneous VD                                                  None                                    Gait difficulty began soon after delivery   Healthy                                                   None
  17                                    Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  18                                    Forceps delivery                                                     None                                    None                                        Healthy                                                   None
  19    Allain et al. ([@B17])          Term spontaneous VD                                                  None                                    None                                        Healthy[^\*^](#TN1){ref-type="table-fn"}                  None
  20    Ball and Sagar ([@B18])         Forceps delivery + epidural anesthesia                               None                                    None                                        Healthy                                                   None
  21    Hagell et al. ([@B15])          Term elective CD                                                     None                                    None                                        Osteomalacia                                              None
  22    Kupsch and Oertel ([@B19])      Term elective CD                                                     None                                    None                                        Healthy                                                   None
  23    Benito-Leon et al. ([@B31])     Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  24    Shulman et al. ([@B24])         Term spontaneous VD                                                  None                                    Postpartum depression                       Healthy                                                   None
  25    De Mari et al. ([@B32])         Term CD (podalic presentation)                                       None                                    None                                        Healthy                                                   None
  26    Mucchiut et al. ([@B34])        CD because motor impairment                                          Motor disability worsened               None                                        Healthy                                                   None
  27a   Scott and Chowedhury ([@B33])   Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  27b                                   Urgent CD for placental abruption (32 weeks)                         None                                    None                                        Healthy                                                   None
  28    Lindh ([@B35])                  Term spontaneous VD                                                  None                                    None                                        Generalized seizures[^\*\*^](#TN2){ref-type="table-fn"}   None
  29a   Campos-Sousa et al. ([@B25])    Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  29b                                   Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  29c                                   Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  29d                                   Term spontaneous VD                                                  None                                    None                                        Healthy                                                   None
  30    Robottom et al. ([@B26])        Term spontaneous delivery                                            Motor disability worsened               None                                        Healthy                                                   For 6 months
  31    Asha et al. ([@B36])            (IVF pregnancy) Term CD for non-reassuring CTG                       None                                    None                                        Healthy                                                   None
  32    Serikawa et al. ([@B40])        CD at 35 weeks (premature rupture of membranes) D/D twin pregnancy   Motor disability worsened               None                                        Ventricular septum defect in one infant                   None
  33    Bernbir et al. ([@B37])         CD at 36 weeks                                                       None                                    None                                        Healthy                                                   None
  34a   Zlotnik et al. ([@B27])         Term spontaneous VD (42 weeks)                                       None                                    None                                        Healthy                                                   Yes
  34b                                   Term spontaneous VD                                                  Severe dyskinesia during labor          None                                        Healthy[^\*\*\*^](#TN3){ref-type="table-fn"}              For 3 months

*The newborn was immediately transferred to the newborn intensive care unit and observed for 8 days without any indication of neurological, vegetative, or metabolic abnormality*.

*One hour after delivery, the infant developed generalized seizures. Phenobarbital was given without effect. Diazepam was added and no further seizures were observed. The baby was also short of breath and had increased CRP, and the chest X-ray showed pneumonia*.

*The newborn at 10 months, 0.1st weight percentiles for age (low weight percentile for age during the first year of life)*.

Comment {#s6}
=======

PD is an age-related disease, and pregnancy in women with PD is very uncommon. The incidence of PD increases with age, although about 5% is diagnosed before the age of 40 ([@B3]). The literature available on pregnancy in PD includes 38 case reports, but the amount of the evidence on the effect of pregnancy on PD and on safety of dopaminergic medications is so far inconclusive. Studies on the impact of pregnancy on PD described no change ([@B16], [@B18], [@B22], [@B25]--[@B27], [@B31]--[@B33], [@B35]--[@B37]), improvement ([@B16], [@B19]), or worsening ([@B15]--[@B17], [@B23], [@B24], [@B26], [@B27], [@B34], [@B40]) of the motor symptoms. Non-motor symptoms seem to worsen during pregnancy as well ([@B16]). Our patient experienced worsening of her motor symptoms during gestation and a need for higher L-DOPA dosage throughout pregnancy. The rapid deterioration during gestation and the clinical stability in the postpartum period support the idea of a deleterious effect of pregnancy on PD, which is probably determined by hormonal modifications or L-DOPA pharmacokinetic alteration induced by pregnancy or both. The main concern for managing pregnancy in PD is the safety of antiparkinsonian medications for the fetus. The remaining antiparkinsonian medications belongs to category C of FD A ([@B21]), which means that animal studies point to some risk, while human studies are either not available or they have not confirmed that risk ([@B39], [@B42]). Based on current knowledge, dopamine agonists do not seem to have abortive or teratogenic effects on pregnancy ([@B25], [@B31]--[@B36]). The most important available data concern the safety of L-DOPA therapy during pregnancy. Animal data indicate that L-DOPA with or without dopa-decarboxylase inhibitors (carbidopa or benserazide) induces some teratogenic risk when given in high doses in animal models ([@B39]). However, in seven cases where L-DOPA was used as monotherapy, there were no reports of a teratogenic effect ([@B22], [@B25]). However, there were two miscarriages in PD patients using L-DOPA ([@B23], [@B26]) and one case of fetal osteomalacia when L-DOPA was associated with benserazide ([@B15]). Amantadine is the only antiparkinsonian medication where administration was associated with cardiovascular malformations in one infant ([@B41]). There is no report of major malformations with the use of selegine ([@B19]), but data are insufficient. Up to now, there is no data available on rotigotine and apomorphine. As for the risk of using antiparkinsonian drugs during breast feeding, here too evidence is fairly limited. Almost all drugs are excreted into breast milk and are bioavailable to the infant ([@B43]), but, generally speaking, concentrations in breast milk are close to or even lower than concentrations in the mother\'s plasma, and the total dose to which the infant is exposed is usually much lower than the therapeutic dose range.

Conclusions {#s7}
===========

It is necessary that obstetricians and neurologists learn how to manage pregnancy in PD patients, to ensure the best possible maternal and fetal outcome. There seems to be some risk of worsening of the condition or upcoming of new PD symptoms during or shortly after pregnancy. Patients with PD considering pregnancy should be informed about this. More data concerning the safety of antiparkinsonian drugs in PD treatment as well as the effect of pregnancy on parkinsonian symptoms are needed. There is also a need for clinical trials to evaluate the use of antiparkinsonian medication in pregnancy. According to the current state of the art, L-DOPA therapy should be considered preferable to other drugs during pregnancy.
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